CB CD34+ cells with up-regulated hTERT expression allowed multilineage differentiation in NOD/SCID mice bone marrow
Group . | No. mice in group . | CD33/15+, % . | CD19+, % . | CD34+, % . |
|---|---|---|---|---|
| dGFP+ | 11 | 36 ± 15 | 54 ± 16 | 8.9 ± 5.0 |
| GFP+ | 8 | 28 ± 4.4 | 67 ± 6.6 | 13 ± 5.0 |
| Mock | 8 | 32 ± 12 | 65 ± 13 | 14 ± 5.0 |
Group . | No. mice in group . | CD33/15+, % . | CD19+, % . | CD34+, % . |
|---|---|---|---|---|
| dGFP+ | 11 | 36 ± 15 | 54 ± 16 | 8.9 ± 5.0 |
| GFP+ | 8 | 28 ± 4.4 | 67 ± 6.6 | 13 ± 5.0 |
| Mock | 8 | 32 ± 12 | 65 ± 13 | 14 ± 5.0 |
Sublethally irradiated NOD/SCID mice received transplants of sorted dGFP+, GFP+, or mock-transduced cells at 1 × 105 cells per animal via tail-vein injection. At 6 weeks after transplantation, the human-cell engraftment and lineage differentiation were assessed in mice bone marrow. Data shown are the averages and standard deviations of the percentages of myeloid, B lymphoid, and CD34+ cells in the CD45+ human cells.